Pathogenesis and Treatment of Adrenal Tumors 2.0

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 2840

Special Issue Editors


E-Mail Website
Guest Editor
Department of Endocrinology, First Department of Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece
Interests: adrenals; pituitary; thyroid; tumorigenesis; diabetes
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN 55905, USA
Interests: adrenals; pituitary; thyroid; diabetes
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Advances in genomics have enormously improved our understanding of adrenal tumorigenesis and led to the development of prognostic markers and therapeutic targets. Bilateral nodular hyperplasias, causing Cushing’s syndrome, are frequently caused by germline alterations, leading to cAMP/PKA pathway activation (micronodular) and ARMC5 inactivation (macronodular). Somatic mutations of β-catenin and PRKACA are observed in non-secreting or cortisol-producing adenomas, respectively. Alterations in the β-catenin (CTNN1B, ZNFR3) or TP53 pathways are found in carcinomas. Mutations in cancers are more common in aggressive tumors and correlate with transcriptome or methylation profiles. Identification of these alterations helps to refine the molecular classification of these tumors and to develop molecular-targeted treatment.

Dr. Anna Angelousi
Dr. Danae Delivanis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • adrenal
  • genes
  • adenoma
  • pheochromocytoma
  • adrenocortical carcinoma
  • adrenal hyperplasia PKA
  • ARMC5
  • b-catenin

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 11213 KiB  
Article
The Enhanced Expression of ZWILCH Predicts Poor Survival of Adrenocortical Carcinoma Patients
by Małgorzata Blatkiewicz, Kacper Kamiński, Marta Szyszka, Zaid Al-Shakarchi, Anna Olechnowicz, Ewelina Stelcer, Hanna Komarowska, Marianna Tyczewska, Anna Klimont, Marek Karczewski, Tomasz Wierzbicki, Joanna Mikołajczyk-Stecyna, Marek Ruchała, Ludwik K. Malendowicz and Marcin Ruciński
Biomedicines 2023, 11(4), 1233; https://doi.org/10.3390/biomedicines11041233 - 21 Apr 2023
Cited by 4 | Viewed by 2391
Abstract
Zwilch kinetochore protein (ZWILCH) plays a key role in proper cell proliferation. The upregulation of the ZWILCH gene was observed in many types of cancers, but the association of ZWILCH with adrenocortical carcinoma (ACC) was not investigated so far. The main aim of [...] Read more.
Zwilch kinetochore protein (ZWILCH) plays a key role in proper cell proliferation. The upregulation of the ZWILCH gene was observed in many types of cancers, but the association of ZWILCH with adrenocortical carcinoma (ACC) was not investigated so far. The main aim of the presented study was to verify if the enhanced level of the ZWILCH gene can be used as a diagnostic marker for ACC development and progression, as well as a predictor of survival time for ACC patients. The performed analyses included investigation of the ZWILCH expression profile in tumors with publicly available TCGA (The Cancer Genome Atlas) datasets and transcriptomic data from the Gene Expression Omnibus (GEO) database, as well as, in human biological samples of normal adrenal, adrenocortical carcinoma and in commercially available tissue microarrays. The findings demonstrate statistically significant higher ZWILCH gene expression in ACC tissue in comparison with normal adrenal glands. Furthermore, there is a strong correlation between ZWILCH upregulation and tumor mitotic rate and the probability of patient survival. The enhanced ZWILCH level is also connected with the activation of genes involved in cell proliferation and the inhibition of genes related to the immune system. This work contributes to a better understanding of the role of ZWILCH as an ACC biomarker and diagnostic tool. Full article
(This article belongs to the Special Issue Pathogenesis and Treatment of Adrenal Tumors 2.0)
Show Figures

Figure 1

Back to TopTop